These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23910940)

  • 1. Reply to Hiten D. Patel and Mohamad E. Allaf's letter to the editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
    Sun M; Karakiewicz PI; Trinh QD
    Eur Urol; 2013 Nov; 64(5):e107-8. PubMed ID: 23910940
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
    Patel HD; Allaf ME
    Eur Urol; 2013 Nov; 64(5):e105-6. PubMed ID: 23910939
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Marc Bjurlin, Elena Elkin, and William Huang's Letter to the Editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol 2014;65:235-41.
    Sun M; Karakiewicz PI
    Eur Urol; 2015 Apr; 67(4):e72. PubMed ID: 25179937
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol 2014;65:235-41.
    Bjurlin M; Elkin EB; Huang WC
    Eur Urol; 2015 Apr; 67(4):e71. PubMed ID: 25179936
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management.
    Laguna MP
    J Urol; 2014 May; 191(5):1262-3. PubMed ID: 24745480
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to E. David Crawford and Bo-Eric Persson's letter to the editor re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026.
    Gandaglia G; Sun M; Briganti A; Karakiewicz PI
    Eur Urol; 2014 Aug; 66(2):e36-7. PubMed ID: 24746970
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026.
    Crawford ED; Persson BE
    Eur Urol; 2014 Aug; 66(2):e34-5. PubMed ID: 24768492
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
    Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
    Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management.
    Sun M; Becker A; Tian Z; Roghmann F; Abdollah F; Larouche A; Karakiewicz PI; Trinh QD
    Eur Urol; 2014 Jan; 65(1):235-41. PubMed ID: 23567066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
    Mollica V; Rizzo A; Massari F
    Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039.
    Tomlins SA; Groskopf J; Chinnaiyan AM
    Eur Urol; 2015 Nov; 68(5):e108. PubMed ID: 26242717
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition.
    Singla N; Margulis V
    Eur Urol; 2020 Aug; 78(2):e79-e80. PubMed ID: 32362497
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Glen Denmer Santok and Koon Ho Rha's Letter to the Editor re: Pär Stattin, Fredrik Sandin, Frederik Birkebæk Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.023.
    Stattin P; Bratt O
    Eur Urol; 2017 Apr; 71(4):e115-e116. PubMed ID: 27720538
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Mengda Zhang and Long Wang's Letter to the Editor re: Francesco Porpiglia, Enrico Checcucci, Daniele Amparore, et al. Three-dimensional Augmented Reality Robot-assisted Partial Nephrectomy in Case of Complex Tumours (PADUA ≥ 10): A New Intraoperative Tool Overcoming the Ultrasound Guidance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.11.024.
    Amparore D; Checcucci E; Fiori C; Porpiglia F
    Eur Urol; 2020 Jun; 77(6):e163-e164. PubMed ID: 32279902
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
    Mori K; Schmidinger M; Egawa S; Gust KM; Shariat SF
    Eur Urol; 2021 Apr; 79(4):e113-e114. PubMed ID: 33487477
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.038.
    Rieken M; Shariat SF
    Eur Urol; 2015 Nov; 68(5):e104-5. PubMed ID: 26314617
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Maxine Sun, Quoc-dien Trinh, Marco Bianchi, et al. A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol 2012;61:725-31.
    Sandhu GS; Tanagho YS; Bhayani SB
    Eur Urol; 2012 Sep; 62(3):e58; author reply e59-60. PubMed ID: 22704368
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Marc A. Bjurlin, Lee C. Zhao, and Michael D. Stifelman's Letter to the Editor Re: Nicolò Maria Buffi, Giovanni Lughezzani, Rodolfo Hurle, et al. Robot-assisted Surgery for Benign Ureteral Strictures: Experience and Outcomes from Four Tertiary Care Institutions. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.022.
    Buffi NM; Lughezzani G; Hurle R; Lazzeri M; Taverna G; Bozzini G; Bertolo R; Checcucci E; Porpiglia F; Fossati N; Gandaglia G; Larcher A; Suardi N; Montorsi F; Lista G; Guazzoni G; Mottrie A
    Eur Urol; 2017 Mar; 71(3):e92-e93. PubMed ID: 27641789
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Evanguelos Xylinas, Michael Rink, Eugene K. Cha, et al. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.04.052.
    Luo HL; Chiang PH
    Eur Urol; 2012 Nov; 62(5):e92-3. PubMed ID: 22906766
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
    de Bono J
    Eur Urol; 2017 Jan; 71(1):e11. PubMed ID: 27751730
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.